论文部分内容阅读
目的探讨雄激素受体和雌激素受体在肺腺癌、鳞癌中的表达及其与预后的关系。方法应用免疫组化SP法检测54例肺腺癌和78例鳞癌组织标本中雄激素受体(AR)和雌激素受体(ER)的表达,并分析其与临床特性及生存率的关系。结果 AR和ER总阳性率分别为21.2%(28/132)和18.2%(24/132)。非小细胞肺癌(NSCLC)组织中AR的阳性表达与TNM分期及N分期(淋巴结转移情况)相关。AR表达阳性组3年生存率显著低于阴性组(21.4%vs.45.2%)(P<0.05);ER表达阳性组3年生存率低于阴性组(29.2%vs.42.6%)(P>0.05)。结论 AR的阳性表达与NSCLC淋巴结转移和肿瘤进展可能相关,并且预后较差。
Objective To investigate the expression of androgen receptor and estrogen receptor in lung adenocarcinoma and squamous cell carcinoma and its relationship with prognosis. Methods The expressions of androgen receptor (AR) and estrogen receptor (ER) in 54 cases of lung adenocarcinoma and 78 cases of squamous cell carcinoma were detected by immunohistochemical SP method. The relationship between them was analyzed with clinical characteristics and survival rate . Results The total positive rates of AR and ER were 21.2% (28/132) and 18.2% (24/132) respectively. The positive expression of AR in non-small cell lung cancer (NSCLC) was correlated with TNM stage and N stage (lymph node metastasis). The 3-year survival rate of AR-positive group was significantly lower than that of negative group (21.4% vs.45.2%, P <0.05). The 3-year survival rate of ER-positive group was lower than that of negative group (29.2% vs.42.6% 0.05). Conclusion The positive expression of AR may be related to lymph node metastasis and tumor progression in NSCLC, and the prognosis is poor.